Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2. - Bräutigam J; Bischoff I; Schürmann C; Buchmann G; Epah J; Fuchs S; Heiss E; Brandes RP; Fürst R (Journal of molecular and cellular cardiology, 2019)